Pharmabiz1h
Minghui Pharma to present phase I/II study results of MHB088C to treat patients with recurrent or metastatic solid tumors at ASCO meeting
Minghui Pharma to present phase I/II study results of MHB088C to treat patients with recurrent or metastatic solid tumors at ASCO meeting: Shanghai Friday, May 10, 2024, 18:00 Hrs ...
Pharmabiz2h
Andall Biosciences launches ovary care capsule, 23WELL
Shanghai Friday, May 10, 2024, 17:00 Hrs [IST] Andall Biosciences Inc (ABI), a renowned biotechnology company at the forefr ...
Pharmabiz3h
Acumen Pharma begins patient dosing in ALTITUDE-AD phase 2 trial of sabirnetug in early Alzheimer’s disease
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AßOs) for the treatment of Alzheimer’s ...
Pharmabiz4h
ENA Respiratory receives US patent covering INNA-051, a first-in-class antiviral innate immunomodulator
ENA Respiratory receives US patent covering INNA-051, a first-in-class antiviral innate immunomodulator: Melbourne, Australia Friday, May 10, 2024, 15:00 Hrs [IST] ENA Respiratory ...
Pharmabiz2h
Recce Pharma receives 2 patents in China for its RECCE 327 and RECCE 529 anti-infectives
Recce Pharmaceuticals Ltd, a company developing new class of synthetic anti-infectives designed to address the urgent global health problems of antibiotic-resistant superbugs and emerging viral ...
Pharmabiz5h
US FDA grants breakthrough therapy designation to Avidity Biosciences’ delpacibart etedesiran to treat myotonic dystrophy type 1
US FDA grants breakthrough therapy designation to Avidity Biosciences’ delpacibart etedesiran to treat myotonic dystrophy type 1: San Diego Friday, May 10, 2024, 14:00 Hrs [IST] ...
Pharmabiz6h
OJSP launches Sudhamukti ayurvedic medicine for diabetes management
OJSP launches Sudhamukti ayurvedic medicine for diabetes management: Our Bureau, Mumbai Friday, May 10, 2024, 13:30 Hrs [IST] OJSP has launched Sudhamukti ayurvedic medicine, a br ...
Pharmabiz1h
Bayer to present results from phase III OASIS 1 and 2 of elinzanetant to treat vasomotor symptoms associated with menopause at ACOG meeting
Bayer will present detailed results from the pivotal phase III studies OASIS 1 and 2 evaluating the efficacy and safety of the investigational compound elinzanetant versus placebo, at the upcoming ...
Pharmabiz9h
NIH to launch long Covid trials to study sleep disturbances, exercise intolerance, and post exertional malaise
NIH to launch long Covid trials to study sleep disturbances, exercise intolerance, and post exertional malaise: Bethesda, Maryland Friday, May 10, 2024, 10:00 Hrs [IST] The Nation ...
Pharmabiz8h
ExcellGene collaborates with Cytovance Biologics to transform large molecule biologics development and production
ExcellGene collaborates with Cytovance Biologics to transform large molecule biologics development and production: Oklahoma City Friday, May 10, 2024, 11:00 Hrs [IST] ExcellGene S ...
Pharmabiz10h
Arbor Biotechnologies acquires Serendipity Biosciences for developing a range of small gene editing tools
Arbor Biotechnologies acquires Serendipity Biosciences for developing a range of small gene editing tools: Cambridge, Massachusetts Friday, May 10, 2024, 09:00 Hrs [IST] Arbor Bio ...
Pharmabiz8h
Omron Healthcare India collaborates with AliveCor India
Omron Healthcare India, the Indian arm of the Japanese global leader in medical equipment for home health monitoring and treatment, has announced its collaboration with AliveCor India, the Indian ...